A landmark ‘evolutionary double-bind’ strategy to overcome treatment resistance in prostate cancer

Many patients with metastatic cancers receive therapy that is initially highly effective, often resulting in complete remission. However, cancer cells have a remarkable capacity to evolve resistance to currently available therapies. As a result, resistant cells eventually proliferate, causing the tumor to recur, leading to treatment failure and ultimately patient death.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup